Previous Close | 45.14 |
Open | 44.99 |
Bid | 43.68 x 400 |
Ask | 43.76 x 400 |
Day's Range | 43.64 - 45.72 |
52 Week Range | 43.64 - 77.32 |
Volume | |
Avg. Volume | 991,791 |
Market Cap | 7.957B |
Beta (5Y Monthly) | 0.01 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Contrarian Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Optimism started to prevail, during the last months of the year, and investors reacted positively to news of a potential change in direction by the US Federal Reserve, as well as […]